US7207951036 - PIRS - A12G4Q (XNCM)
PIERIS PHARMACEUTICALS INC Aktie
18,05 USD
Aktuelle Kurse von PIERIS PHARMACEUTICALS INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
PIRS
|
USD
|
20.09.2024 01:54
|
18,05 USD
| 16,16 USD | 11,70 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | 8,28 % | 7,28 % | 95,45 % | 4,70 % | -28,14 % | -95,73 % |
Firmenprofil zu PIERIS PHARMACEUTICALS INC Aktie
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Unternehmensdaten zur PIERIS PHARMACEUTICALS INC Aktie
Name PIERIS PHARMACEUTICALS INC
Firma Pieris Pharmaceuticals, Inc.
Symbol PIRS
Website https://www.pieris.com
Heimatbörse
NASDAQ CAPITAL MARKET
WKN A12G4Q
ISIN US7207951036
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Stephen S. Yoder J.D.
Marktkapitalisierung 24 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,0 T
Adresse 255 State Street, 02109 Boston
IPO Datum 2015-01-02
Aktien-Splits
Datum | Split |
---|---|
23.04.2024 | 1:80 |
Ticker Symbole
Name | Symbol |
---|---|
NASDAQ | PIRS |
Weitere Aktien
Investoren die PIERIS PHARMACEUTICALS INC halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024